IVA · Inventiva S.A.

The thesis

Inventiva's case still rests on one event: the fourth-quarter 2026 topline result from the NATiV3 Phase 3 trial of lanifibranor in MASH (metabolic dysfunction-associated steatohepatitis, a fatty-liver disease). The American depositary shares closed at $3.69 on 27 October 2026, 48.5% below the 52-week high of $7.15, and the readout settles whether the case holds.

The timeline has not changed. Inventiva's 6 October 2026 release repeated that topline results are expected in the fourth quarter of this year, and a search of company announcements through 28 October 2026 found no results and no date. The shares have recovered from the $2.87 close of 14 October 2026 to $3.69 while Piper Sandler maintained Buy with a $26 price target on 24 October 2026. The narrative is maturing: the story is well known and analyst-supported, and attention has moved to the AASLD (American Association for the Study of Liver Diseases) meeting beginning 5 November 2026 and the undated readout.

Bullish and bearish views on Inventiva S.A.

The bull case on Inventiva S.A. (IVA), in brief: Trial treatment is finished. The bear case: Funding is conditional.

Bull case

• Trial treatment is finished. Inventiva announced on 2 September 2026 that the last patient completed the 72-week visit. The company repeated Q4 2026 topline in its 28 September 2026 and 6 October 2026 releases.
• Analyst targets sit far above the price. Piper Sandler maintained Buy with a $26 target on 24 October 2026. Canaccord Genuity raised its target to $21 on 29 September 2026, Truist Securities raised its target to $18 on 2 October 2026, and Cantor Fitzgerald initiated at Overweight on 17 July 2026.
• Management guides funding to the end of Q2 2027.
• A large trial sets up a clear answer. NATiV3 enrolled 1,009 adults with biopsy-proven MASH and F2/F3 fibrosis, plus 410 patients in an exploratory cohort, per company announcements. A regulatory filing is planned for H1 2027 if results are favorable.

Bear case

• Funding is conditional. The 28 September 2026 release says current cash does not cover the next twelve months of planned operations.
• There is no revenue. First-half 2026 revenue was €20,000 against €4.5 million in the first half of 2025, and the net loss was €69.5 million (Inventiva, 28 September 2026).
• One asset carries the company. A miss on the fibrosis endpoint leaves no second program.
• The rebound is recent and the shares remain well below prior prices. The close was $3.69 on 27 October 2026 against the $4.40 June 2026 offering price and the $7.15 52-week high. The three-month price change was -20.2% as of 27 October 2026.

Price setup

The close on 27 October 2026 was $3.69. The 14-day relative strength index (RSI, a 0–100 momentum gauge) was 59.1, up from 39.9 on 14 October 2026, so momentum has moved from weak to neutral-positive in two weeks.

The shares closed $2.87 on 14 October 2026 and have since moved well above the $2.85 prior-cycle low. The $4.40 June offering price sits above the current close, and the $7.15 52-week high is the next reference level overhead. The readout has no announced date, so the price can move on a date announcement as well as on the data.

Crowding evidence: Ortex reported on 30 September 2026 a cost to borrow of 14.1% and borrow availability of 7.8%, a sign of heavy short interest at that reading. A rebound can partly reflect short covering. Foreign private issuers file no Form 4s, so there is no US insider-transaction data. The company sold new American depositary shares at $4.40 on 2 June 2026, and a further equity raise ahead of data remains possible.

Catalysts, next 30 days

• 5 November to 9 November 2026: AASLD The Liver Meeting, Denver. Inventiva will present three lanifibranor posters (release of 6 October 2026). The posters cover existing data, not the NATiV3 result.
• ~2026-Q4 (est., undated): NATiV3 topline. The company gives no date. A date announcement or the result can land in any week, including inside this window.

Elapsed catalysts

• ~31 October 2026 (est.): shareholder approval of warrant terms. Financing disclosures indicate approval was expected by this date. Approval bears on the Tranche 3 warrants that the Q1 2028 runway depends on. (passed 6d ago)

What would change the view

The case breaks if the NATiV3 topline misses the fibrosis improvement endpoint, shows a safety finding that stops development, or slips out of the fourth quarter of 2026 in company language.

On price, a daily close below $2.70, under the $2.85 prior-cycle low and the $2.87 close of 14 October 2026, would show the market pricing a failed readout and erase the recent rebound.

What it trades with

Inventiva trades on its own trial outcome rather than on a sector factor. The American depositary shares also follow the Paris listing, so euro-dollar moves and the Euronext session affect the US price. Other MASH developers' news can move sentiment, but the NATiV3 result is the only event the company's value turns on.